Refractory cutaneous pseudolymphoma treated with tapinarof.

Q3 Medicine
Baylor University Medical Center Proceedings Pub Date : 2025-04-09 eCollection Date: 2025-01-01 DOI:10.1080/08998280.2025.2487381
Shravya Kichena, Emily Limmer, Dario Kivelevitch
{"title":"Refractory cutaneous pseudolymphoma treated with tapinarof.","authors":"Shravya Kichena, Emily Limmer, Dario Kivelevitch","doi":"10.1080/08998280.2025.2487381","DOIUrl":null,"url":null,"abstract":"<p><p>Cutaneous pseudolymphoma (CPL) is a reactive polyclonal T- or B-cell lymphoproliferative process that histopathologically and/or clinically imitates cutaneous lymphoma. We report the case of a 62-year-old woman with a poorly defined, erythematous plaque with papules on the dorsal nose that had been present for years. This lesion was biopsied as an atypical T-cell infiltrate and was clinically diagnosed as a pseudolymphoma. After unsuccessful treatments with mometasone and tacrolimus, the patient was started on tapinarof cream 1%. After 10 months of treatment, there was clinical improvement of the plaque and papules with only slight residual erythema. Further studies and reports will help elucidate the role of tapinarof as a therapeutic option for pseudolymphoma. Based on its safety profile and promising results in other inflammatory and hyperproliferative disorders, it could be considered in refractory cases.</p>","PeriodicalId":8828,"journal":{"name":"Baylor University Medical Center Proceedings","volume":"38 5","pages":"755-757"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12351737/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Baylor University Medical Center Proceedings","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/08998280.2025.2487381","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Cutaneous pseudolymphoma (CPL) is a reactive polyclonal T- or B-cell lymphoproliferative process that histopathologically and/or clinically imitates cutaneous lymphoma. We report the case of a 62-year-old woman with a poorly defined, erythematous plaque with papules on the dorsal nose that had been present for years. This lesion was biopsied as an atypical T-cell infiltrate and was clinically diagnosed as a pseudolymphoma. After unsuccessful treatments with mometasone and tacrolimus, the patient was started on tapinarof cream 1%. After 10 months of treatment, there was clinical improvement of the plaque and papules with only slight residual erythema. Further studies and reports will help elucidate the role of tapinarof as a therapeutic option for pseudolymphoma. Based on its safety profile and promising results in other inflammatory and hyperproliferative disorders, it could be considered in refractory cases.

tapinarof治疗难治性皮肤假性淋巴瘤。
皮肤假性淋巴瘤(CPL)是一种反应性多克隆T细胞或b细胞淋巴细胞增生过程,其组织病理学和/或临床模拟皮肤淋巴瘤。我们报告的情况下,62岁的妇女与一个不明确,红斑斑块与丘疹的鼻背,已经存在多年。活检显示为非典型t细胞浸润,临床诊断为假性淋巴瘤。在莫米松和他克莫司治疗不成功后,患者开始使用1%的tapinarof霜。治疗10个月后,斑块和丘疹均有临床改善,仅残留少量红斑。进一步的研究和报道将有助于阐明tapinarof作为假性淋巴瘤的治疗选择的作用。基于其安全性和在其他炎症和增生性疾病中的良好效果,它可以被考虑用于难治性病例。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.30
自引率
0.00%
发文量
245
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信